Reply to “Prophylactic Allogeneic Hematopoietic Stem Cell Therapy for CSF1R-Related Leukoencephalopathy”

Philip W. Tipton, Daniel Kenney-Jung, Beth K. Rush, Erik H. Middlebrooks, David Nascene, Balvindar Singh, Shernan Holtan, Ernesto Ayala, Daniel F. Broderick, Troy Lund, Zbigniew K. Wszolek

Research output: Contribution to journalLetterpeer-review

Original languageEnglish (US)
Pages (from-to)1109-1110
Number of pages2
JournalMovement Disorders
Issue number5
StatePublished - May 2022

Bibliographical note

Funding Information:
E.H.M. receives research support from Mayo Clinic Focused Team Research program; Mayo Clinic Research Accelerator for Clinicians Engaged in Research program; Boston Scientific Corp; Varian Medical Systems, Inc.; and the National Institutes of Health (R33‐CA240181). He is also consultant for Boston Scientific Corp.

Funding Information:
Z.K.W. is partially supported by the NIH/NIA and NIH/NINDS (1U19AG063911, FAIN: U19AG063911), Mayo Clinic Center for Regenerative Medicine, and Mayo Clinic in Florida Focused Research Team Program and the gifts from the Donald G. and Jodi P. Heeringa Family and the Haworth Family Professorship in Neurodegenerative Diseases fund, the Albertson Parkinson's Research Foundation, and Ann B. Smith Research Fund. He serves as Principal investigator or co‐principal investigator for Biohaven Pharmaceuticals, Inc. (BHV4157‐206 and BHV3241‐301); Neuraly, Inc. (NLY01‐PD‐1); and Vigil Neuroscience, Inc. (VGL101‐01.001 and VGL101‐01.002). He serves as co‐PI for the Mayo Clinic APDA Center for Advanced Research and as an external advisory board member for the Vigil Neuroscience, Inc.

Funding Information:
D.K.‐J. is partially supported by grants from the Rare Disease Foundation and CFC International and is Co‐I on Bluebird Pharmaceuticals (ALD‐102, ALD‐103, and ALD‐104).


  • CSF1R-related leukoencephalopathy
  • genetics; treatment
  • stem cell transplantation

Cite this